Bone Biologics Corp Stock Today
| BBLGW Stock | USD 27.80 0.69 2.42% |
Performance4 of 100
| Odds Of DistressOver 80
|
Bone Biologics is selling for under 27.80 as of the 29th of November 2024; that is 2.42 percent down since the beginning of the trading day. The stock's lowest day price was 27.8. Bone Biologics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Bone Biologics Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of August 2024 and ending today, the 29th of November 2024. Click here to learn more.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. More on Bone Biologics Corp
Moving together with Bone Stock
Moving against Bone Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bone Stock Highlights
| CEO President | Jeffrey Frelick |
| Thematic Idea | Medical Equipment (View all Themes) |
| Business Concentration | Medical Equipment, Medical Devices, Healthcare, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) |
Bone Biologics Corp (BBLGW) is traded on NASDAQ Exchange in USA. It is located in 2 Burlington Woods Drive, Burlington, MA, United States, 01803 and employs 2 people. Bone Biologics is listed under Medical Equipment category by Fama And French industry classification. The company classifies itself under Health Care Equipment & Supplies sector and is part of Health Care industry.
Bone Biologics Corp has accumulated about 4.44 K in cash with (9.56 M) of positive cash flow from operations.
Check Bone Biologics Probability Of Bankruptcy
Bone Biologics Corp Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bone Biologics market risk premium is the additional return an investor will receive from holding Bone Biologics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0515 | |||
| Jensen Alpha | 1.39 | |||
| Total Risk Alpha | (2.32) | |||
| Treynor Ratio | (1.84) |
Bone Stock Against Markets
Bone Biologics Corporate Executives
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda | CoFounder Board | Profile |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.